• Japanese
  • Korean
  • Chinese
Cover Image

Medical Device Leader Series: Top Needle-Free Injection Device Manufacturers 2014-2024

Needle-free injecting technologies - discover activities, developments, and prospects of leading companies

What does the future hold for makers of needle-free injection (NFI) products? See what's possible. Visiongain's updated report shows you data to 2024 for that industry and market. There you find analysis, trends, opportunities, and forecasting of revenues.

Our study analyses 14 leading developers and producers of those medical devices. You can now explore the future of NFI to introduce drugs, finding its potential. Discover how you can benefit.

Forecasts and other data for staying ahead in knowledge of those medical injectors

There you examine the industry for needleless injection and needle-free syringes - insulin injectors and other systems. Find what's happening. Potential exists for novel and improved subcutaneous, intradermal, intramuscular, and intravenous drug delivery.

That industry advances. In our report you assess product ranges, historical data, R&D, market shares, sales predictions, and growth rates. There you get quantitative and qualitative analyses. You also find 42 tables, 17 charts and three research interviews.

NFI technology - discover how to help your work, also finding where money lies

Avoid missing out. See how developers overcome problems with parenteral drug application, esp. benefiting use of biological drugs (biologics). You also discover potential revenues.

So the following sections outline what you get in our investigation.

Companies based in North America - what're their outlooks?

First our study gives you financial data and discussions for prominent North American NFI developers and manufacturers:

  • Antares Pharma
  • Bioject Medical Technologies
  • Zogenix
  • Activa
  • D'Antonio Consultants International.

You also find profiles of these organisations:

  • National Medical Products
  • Medical International Technologies
  • Penjet Corporation
  • PharmaJet
  • Valeritas.

Discover what the present and future hold for those companies. Also find the money. See revenue predictions to 2024 for the overall world industry for needle-free injection devices.

Hear, too, about developments and prospects of competitors in other countries.

Europe - outlooks for leading developers and producers of medical injection technology

Next our report analyses European-based specialists in that drug delivery:

  • Akra Dermojet
  • Crossject Medical Technology
  • Injex Pharma
  • Glide Pharma.

Many commercial opportunities exist, with expanding revenues possible this decade. Discover the best potentials. You find how companies gain advantages and raise sales.

In that work you see what affects the future - what influences success.

Events and forces for developing, producing, marketing, and selling NFI technologies

Our study explains issues affecting that industry and market from 2013 onwards, including these:

  • Applications - pain management, vaccine delivery, treating diabetes, paediatric medicine, and other therapies
  • Regulations in the US and Europe
  • Developments stimulating and restraining that market, inc. allied and competing products.

You also investigate these forces:

  • Jet injector devices, transdermal patches, microneedles, pen injectors, and other therapeutic systems
  • Solid formulations and other challenges, innovations, and progress in therapy
  • Deals, collaborations, and other changes affecting that sector.

There you explore political, economic, social, and technological questions, investigating outlooks for business. Examine what stimulates and restrains that industry and market.

You discover, then, what the present and future hold. You also read opinions from our survey of companies. Stay ahead for information.

Ways Medical Device Leader Series: Top Needle-Free Injection Device Manufacturers 2014-2024 helps you

In particular, our report gives you the following knowledge:

  • Profiles of 14 leading companies - assess products, strategies, and results
  • Competition and opportunities - explore what affects the needle-free injectors industry, finding what influences its sales and determines its future
  • Revenues to 2024 for that market at world level - discover prospects for success.

That work helps people interested in the future of pharmaceuticals and related instruments, containers, and accessories.

Analysis found nowhere else - discover the future of those devices and applications

Our work gives independent analysis. There you receive business intelligence found only in our report. You're free to choose, and our work lets you discover where the money lies.

With that investigation you're less likely to fall behind in information or miss opportunity. See there how you could benefit your research, analysis, and decisions. So avoid missing out.

Also find how you could save time and get recognition for insight, raising your influence.

Table of Contents

1. Executive Summary

  • 1.1 Leading NFI Device Manufacturers: Overview of Findings
  • 1.2 Chapters in the Report
  • 1.3 Research and Analysis Methods
  • 1.4 Aims, Scope and Format of the Report
  • 1.5 Glossary of Terms

2. Introduction to Needle-Free Injection

  • 2.1 What is Needle-Free Drug Delivery?
    • 2.1.1 History of Needle-Free Injections: From Military to Clinic
    • 2.1.2 Modern Needle-Free Devices: Concept of High Pressure Fluid Jet
  • 2.2 What is the Rationale for Needle-Free Injections?
  • 2.3 Applications of Needle-Free Drug Delivery
    • 2.3.1 Pain Management: Using NFI Devices to Administer Lidocaine
    • 2.3.2 Vaccine Delivery: Improving Immune Response
    • 2.3.3 Insulin Delivery: Jet Injection Enhances Drug Distribution
    • 2.3.4 Paediatrics: Alleviating Childhood Anxiety and Phobia
  • 2.4 Regulation of Needle-Free Delivery Devices
    • 2.4.1 The US Regulation System: Prolonged Approval Process
    • 2.4.2 The European Regulation System: Manufacturers Seeking EU Approval First?
  • 2.5 Advantages and Disadvantages of Needle-Free Systems

3. The Global Needle-Free Injection Device Market, 2013-2024

  • 3.1 The Global Needle-Free Injection Device Market, 2012
  • 3.2 The Global Needle-Free Injection Device Market: Revenue Forecast, 2013-2024
  • 3.3 How Will the Market Shares of Leading Sectors Change From 2013-2024?
  • 3.4 What Will Drive the Global Needle-Free Injection Device Market Between 2014 and 2024?
  • 3.5 What Factors are Likely to Restrain the Global Needle-Free Injection Device Market Between 2014 and 2024?
  • 3.6 The Global Jet Injector Device Market, 2012
    • 3.6.1 The Global Jet Injector Device Market: Revenue Forecast, 2013-2024
    • 3.6.2 The Global Jet Injector Device Market: Industry Trends, 2013-2024
  • 3.7 The Global Competing Technologies Market, 2012
    • 3.7.1 The Global Competing Technologies Market: Revenue Forecast, 2013-2024
    • 3.7.2 The Global Competing Technologies Market: Industry Trends, 2013-2024
      • 3.7.2.1 Transdermal Patches: Attractive and Cheap Option
      • 3.7.2.2 Microneedle Technology: Huge Potential for Mass Vaccinations
      • 3.7.2.3 Metered Dose Inhalers: Change in Device Propellant to Drive Adoption

4. The Leading North American Needle-Free Injection Device Manufacturers, 2013

  • 4.1 Antares Pharma
    • 4.1.1 Needle-Free Products
      • 4.1.1.1 Vision™: Delivering Liquid Insulin or Human Growth Hormone
      • 4.1.1.2 Vibex™: Hidden Needle to Alleviate Patient Fear
      • 4.1.1.3 Pen Injector: Devices Being Used Clinical Testing
    • 4.1.2 Sales Performance, 2012
    • 4.1.3 Needle-Free Injection Device Pipeline
      • 4.1.3.1 Vibex™ MTX: Targeting Growing Population of RA Sufferers
      • 4.1.3.2 Vibex™ QS (QuickShot): Modified Vibex to Offer Improved Function
      • 4.1.3.3 OTREXUP™: Combining Vibex MTX and Methotrexate
  • 4.2 Bioject Medical Technologies
    • 4.2.1 Needle-Free Products
      • 4.2.1.1 Biojector® 2000: Adaptable Power Source Allows Use in Home and Mass Vaccination Setting
      • 4.2.1.2 Vitajet™: Low-cost Insulin Delivery System
      • 4.2.1.3 ZetaJet™: Auto-disable Feature Improves User Safety
    • 4.2.2 Sales Performance
    • 4.2.3 Needle-Free Injection Device Pipeline
      • 4.2.3.1 Intradermal Pen Injector: Targeted Drug Delivery
      • 4.2.3.2 Iject®: Providing Tailored Depth of Penetration
      • 4.2.3.3 Jupiter Jet: Multi Dosing With Single Loaded Syringe
    • 4.2.4 Collaborations
      • 4.2.4.1 MPI Research: Seeking Drug/Device Combinations
      • 4.2.4.2 World Health Organisation (WHO): the Push to Eradicate Infectious Disease in Developing Countries
  • 4.3 Zogenix
    • 4.3.1 Needle-Free Products
      • 4.3.1.1 Sumavel® DosePro®: Rapid Acting Migraine Relief
    • 4.3.2 Sales Performance, 2012
    • 4.3.3 Needle-Free Injection Device Pipeline
      • 4.3.3.1 Relday™: Needle-based Alterative for Improved Drug Distribution
    • 4.3.4 Collaborations
    • 4.3.5 Manufacturing
  • 4.4 Activa Brand Products, Inc.
    • 4.4.1 Technology: the Activa Family for Diabetics
    • 4.4.2 Needle-Free Products
      • 4.4.2.1 Product Advantages
  • 4.5 D'Antonio Consultants International Inc. (DCI)
    • 4.5.1 Needle-Free Products
      • 4.5.1.1 LectraJet®: Lightweight Device Reduces User Fatigue
    • 4.5.2 Needle-Free Injection Device Pipeline
      • 4.5.2.1 Low Workload Jet Injector: Single-shot Manuel System
      • 4.5.2.2 Multi Channel Jet Injector: For Simultaneous Vaccine Delivery
  • 4.6 National Medical Products, Inc.
    • 4.6.1 Needle-Free Products
      • 4.6.1.1 J-Tip®: Offering Needle-free Administration of Anaesthesia
  • 4.7 Medical International Technologies
    • 4.7.1 Needle-Free Products
      • 4.7.1.1 MED-JET®: Extremely Thin Orifice Offers Improved Drug Absorption
    • 4.7.2 Sales Performance, 2012
    • 4.7.3 Increased Awareness Through Globalisation
  • 4.8 Penjet Corporation
    • 4.8.1 Needle-Free Products
      • 4.8.1.1 Penjet®: Nitrogen-powered Device Allows Efficient Storage
    • 4.8.2 Applications
      • 4.8.2.1 Multi-Component Drugs
      • 4.8.2.2 Lyophilised Drug Delivery
      • 4.8.2.3 Small Pox Vaccination
  • 4.9 PharmaJet
    • 4.9.1 Needle-Free Products
      • 4.9.1.1 STRATIS®: Drug Delivery in Less Than a Second
    • 4.9.2 Applications
    • 4.9.3 Collaborations: Pursuing a Drug/Device Combination for Vaccine Administration
  • 4.10 Valeritas
    • 4.10.1 Needle-Free Products
      • 4.10.1.1 Mini-Ject™: Potential Delivery of Lyophilised Drugs May Open Huge Opportunities for Valeritas

5. The Leading European Needle-Free Injection Device Manufacturers, 2013

  • 5.1 Akra Dermojet
    • 5.1.1 Needle-Free Products
      • 5.1.1.1 Dermojet® "HR": User-Friendly Design Allows Use in High Intensive Applications
      • 5.1.1.2 DERMOJET Polymedical®: Interchangeable Injection Tips Reduces Risk of Contamination
      • 5.1.1.3 Automatic DERMOJET®
  • 5.2 Crossject Medical Technology
    • 5.2.1 Technology: Highly Customisable Device Allows Tailoring to Specific Drugs
    • 5.2.2 Needle-Free Products
      • 5.2.2.1 Zeneo®: Gas Propellant Generated Upon Injection
  • 5.3 Injex Pharma AG
    • 5.3.1 Needle-Free Products
      • 5.3.1.1 INJEX30®: First Multiple Application Needle-Free Device?
  • 5.4 Glide Pharma
    • 5.4.1 Needle-Free Products
      • 5.4.1.1 Glide SDI®
      • 5.4.1.2 Applications
    • 5.4.2 Advantages
      • 5.4.2.1 Injecting Solid Formulations
      • 5.4.2.2 Pharmaceutical Companies
    • 5.4.3 Collaboration with Pfenex Inc. to Aid Delivery of Solid Dose Vaccine

6. Qualitative Analysis of the Global Needle-Free Injection Device Market, 2013-2024

  • 6.1 SWOT Analysis of the Global Needle-Free Injection Device Market, 2013-2024
    • 6.1.1 Strengths
      • 6.1.1.1 A Less Painful Alternative to Needle-Based Injections
      • 6.1.1.2 No Specialist Training Required for Delivery
      • 6.1.1.3 Reduced Transport Costs
    • 6.1.2 Weaknesses
      • 6.1.2.1 Expensive Technology
      • 6.1.2.2 Inefficient Manufacturing Process
      • 6.1.2.3 Off Patent/Generics Require Reformulating Prior to Use in Needle-Free Delivery Systems
    • 6.1.3 Opportunities
      • 6.1.3.1 Emerging Economies
      • 6.1.3.2 Mass Immunisation Programmes
      • 6.1.3.3 Potential Delivery of Vaccines
      • 6.1.3.4 Patent Expiry of Leading Drugs will Increase Competition
    • 6.1.4 Threats
      • 6.1.4.1 Traditional Needles and Syringes are Cheap to Mass Produce
      • 6.1.4.2 Limited Clinical Data
      • 6.1.4.3 Increased Scrutiny from Regulatory Bodies
      • 6.1.4.4 Medical Device Excise Tax
  • 6.2 STEP Analysis of the Global Needle-Free Injection Device Market, 2013-2024
    • 6.2.1 Social Factors
    • 6.2.2 Technological Developments
    • 6.2.3 Economical Pressures
    • 6.2.4 Political Issues

7. Opinions from Our Industry Survey

  • 7.1 Interview with Zogenix Technologies
    • 7.1.1 Recent Technological Developments in Needle-Free Systems
    • 7.1.2 Competing Technologies and Market Opportunities
    • 7.1.3 Market Restraints and Future Directions
  • 7.2 Interview with Bioject Medical Technologies
    • 7.2.1 Finding a Competitive Edge over Market Rivals
    • 7.2.2 Market Dynamics and Company Collaborations
    • 7.2.3 Potential of Emerging Markets and Regulatory Concerns
  • 7.3 Interview with Team Consulting
    • 7.3.1 Historical Development of the Needle-Free Market
    • 7.3.2 Company Activities and Overcoming the Skin Barrier
    • 7.3.3 Challenges and Limits to Market Growth
    • 7.3.4 Prospects for the Needle-Free Market

8. Conclusions

  • 8.1 The Global Needle-Free Injection Device Market, 2013-2024
  • 8.2 Zogenix Dominated the Global Needle-Free Injection Device Market in 2012
  • 8.3 Strong Company Pipeline Will Help Drive the Market
  • 8.4 Concluding Remarks

List of Tables

  • Table 1.1 Currency Exchange Rates
  • Table 2.1 Examples of Needle-Free Vaccine Delivery Systems, 2013
  • Table 2.2 Examples of Needle-Free Insulin Delivery Systems, 2013
  • Table 2.3 Advantages and Disadvantages of Needle-Free Injection, 2013
  • Table 3.1 The Global Needle Free Injection Device Market: Revenue ($m) and Market Share (%) by Technology, 2012
  • Table 3.2 The Global Needle-Free Injection Device Market: Revenue Forecast ($m, AGR %, CAGR %) by Technology, 2013-2024
  • Table 3.3 The Global Needle-Free Injection Device Market: Market Share (%) by Technology, 2013-2024
  • Table 3.4 The Global Needle-Free Injection Device Market: Drivers and Restraints, 2013-2024
  • Table 3.5 Patent Expiries for Leading Drugs, 2014-2016
  • Table 3.6 Classification of Jet Injector Devices, 2013
  • Table 3.7 The Global Jet Injection Device Market: Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
  • Table 3.8 The Global Competing Needle-Free Technologies Market: Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
  • Table 3.9 Insulin Inhalation Systems in Development, 2013
  • Table 3.10 Vaccine Inhalers in Development, 2013
  • Table 4.1 Antares Pharma: Key Facts, 2013
  • Table 4.2 Antares Pharma Licensing Partnerships, 2013
  • Table 4.3 Antares Pharma: Revenue ($m) & Revenue Share (%) by Business Segment, 2012
  • Table 4.4 Antares Pharma: Product Revenue ($m, CAGR %) by Category, 2010-2012
  • Table 4.5 Bioject Medical Technologies: Key Facts, 2013
  • Table 4.6 Bioject: Revenue ($m) and Revenue Share (%), by Product Line, 2010
  • Table 4.7 Bioject: Summary of Technologies
  • Table 4.8 Zogenix: Key Facts, 2013
  • Table 4.9 Zogenix: Summary of Technology
  • Table 4.10 Zogenix: Revenue ($m) and Revenue Share (%) by Business Segment, 2012
  • Table 4.11 Activa Brand Products: Key Facts, 2013
  • Table 4.12 D'Antonio Consultants: Key Facts, 2013
  • Table 4.13 National Medical Products: Key Facts, 2013
  • Table 4.14 Medical International Technologies: Key Facts, 2013
  • Table 4.15 Medical International Technologies: Revenue ($m, CAGR %), 2009-2012
  • Table 4.16 PenJet Corporation: Key Facts, 2013
  • Table 4.17 PharmaJet: Key Facts, 2013
  • Table 4.18 Valeritas: Key Facts, 2013
  • Table 5.1 Akra Dermojet: Key Facts, 2013
  • Table 5.2 Akra Dermojet: Summary of Technology
  • Table 5.3 Crossject Medical Technology: Key Facts, 2013
  • Table 5.4 Injex Pharma AG: Key Facts, 2013
  • Table 5.5 Glide Pharma: Key Facts, 2013
  • Table 6.1 SWOT Analysis of the Global Needle-Free Injection Device Market, 2013-2024
  • Table 6.2 Average Price for Needle-Free Drug/Vaccine Delivery Technology, 2013
  • Table 6.3 Patent Expiries for Leading Drugs, 2014-2016
  • Table 6.4 The Global Needle-Free Injection Market: STEP Analysis, 2013-2024
  • Table 8.1 The Global Needle-Free Injection Device Market: Revenue Forecast ($m, AGR %, CAGR %) and Market Share (%) by Technology, 2012, 2015, 2018, 2021 and 2024

List of Figures

  • Figure 3.1 The Global Needle Free Injection Device Market: Share (%) by Technology, 2012
  • Figure 3.2 The Global Needle Free Injection Device Market: Revenue ($m) by Technology, 2012
  • Figure 3.3 The Global Needle-Free Injection Device Market: Revenue Forecast ($m), 2013-2024
  • Figure 3.4 The Global Needle-Free Injection Device Market: Share (%) by Technology, 2018
  • Figure 3.5 The Global Needle-Free Injection Device Market: Share (%) by Technology, 2024
  • Figure 3.6 The Global Jet Injection Device Market: Revenue Forecast ($m), 2013-2024
  • Figure 3.7 The Global Competing Needle-Free Technologies Market: Revenue Forecast ($m), 2013-2024
  • Figure 4.1 Antares Pharma: Revenue Share (%) by Business Segment, 2012
  • Figure 4.2 Antares Pharma: Product Revenue ($m) by Category, 2010-2012
  • Figure 4.3 Bioject: Revenue Share (%) by Product Line, 2010
  • Figure 4.4 Bioject: Revenue ($m), 2010-2012
  • Figure 4.5 Zogenix: Revenue Share (%) by Business Segment, 2012
  • Figure 4.6 Zogenix: Revenue ($m) by Business Segment, 2010-2012
  • Figure 4.7 Medical International Technologies: Revenue ($m), 2009-2012
  • Figure 6.1 The Transport Process for a Vaccine
  • Figure 8.1 The Global Needle-Free Injection Device Market: Revenue Forecast ($m) by Technology, 2012, 2015, 2018, 2021 and 2024
  • Figure 8.2 The Global Needle-Free Injection Device Market: Leading Companies by Revenue ($m), 2012

Companies Listed

  • 3M
  • Actavis
  • Activa Brand Products
  • Aerogen
  • Akra Dermojet
  • ALZA Pharmaceuticals
  • Ankara University
  • Antares Pharma
  • Aradigm Corporation
  • Astellas Pharma
  • AstraZeneca
  • Battelle
  • Bill and Melinda Gates Foundation
  • Bioject Medical Technologies
  • BioValve Technologies
  • Bristol-Myers Squibb
  • Cambridge Consultants
  • CDC Measles Eradication Committee
  • Centre for Devices and Radiological Health (CDRH)
  • Centre for Disease Control and Prevention (CDC)
  • China State Food and Drug Administration (SFDA)
  • Covidien
  • Crossject Medical Technology
  • CSL Behring
  • CSL Limited
  • Daewoong Pharmaceuticals
  • Dance Pharmaceuticals
  • D'Antonio Consultants International
  • Diabetes Management International
  • Dr. Reddy's Laboratories
  • Durect Corporation
  • Echo Therapeutics
  • Eli Lilly
  • Eurojet Medical
  • European Union
  • Ferndale Pharma Group
  • Ferring Pharmaceuticals
  • Food and Drug Administration (FDA)
  • Georgia Tech University
  • GlaxoSmithKline (GSK)
  • Glide Pharma
  • Harvard University
  • Injex Pharma AG
  • JCR Pharmaceuticals
  • Jiangsu Hualan Medical International Technologies
  • Johnson & Johnson
  • Mallinckrodt Pharmaceuticals
  • MannKind
  • Meda Pharmaceuticals
  • Medical International Technologies
  • MedImmune
  • Merck & Co.
  • Merck Serono
  • MGlas AG
  • Minnesota Rubber and Plastics (MRP)
  • MPI Research
  • Mylan
  • National Medical Products
  • Nektar Therapeutics
  • North Carolina University
  • Novartis
  • Novo Nordisk
  • Nypro Limited
  • Patheon
  • Penjet Corporation
  • Pfenex Inc.
  • Pfizer
  • PharmaJet
  • Philips Medical
  • Sanofi-Aventis
  • Sanofi-Pasteur
  • Takeda
  • Team Consulting
  • Teva Pharmaceuticals
  • UCB
  • University of Colorado
  • US Army Medical Research Institute of Infectious Disease (USAMRIID)
  • Valeritas
  • Vaxxas
  • Weston Medical
  • World Health Organization (WHO)
  • Zogenix
  • Zomajet
  • Zosano Pharma
Show More
Pricing
Get Notified
Email me when related reports are published